Klaira

Dienogest and Estradiol valerate, the active ingredients in Klaira, are a combined oral contraceptive presented as a tablet for oral use. They prevent pregnancy in women of reproductive age.

GNH USA supplies Klaira as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Klaira, a combined oral contraceptive, is used to prevent pregnancy by inhibiting ovulation.

- Contraception (prevention of pregnancy): provides reliable hormonal birth control for women of child‑bearing potential.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: discomfort or swelling of the breasts. - Irregular bleeding: spotting or changes in menstrual flow.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Severe allergic reaction: rash, swelling, or difficulty breathing.

Klaira should be used with caution and under medical supervision. - Contraindicated in pregnancy: must not be taken during pregnancy. - Contraindicated in active thromboembolic disease: avoid use if clotting disorders are present. - Avoid in smokers over 35 years: increased cardiovascular risk. - Monitor blood pressure regularly: hormonal contraceptives may elevate blood pressure. - Store at ambient temperature: keep in the original pack, protect from moisture.

Klaira may interact with other medicines, requiring attention to avoid reduced efficacy or increased risk.

Major Interactions (Avoid): - Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): may lower contraceptive effectiveness. - Rifampin: reduces hormone levels, risking contraceptive failure. - St. John’s wort: herbal inducer that can diminish drug exposure. - Griseofulvin: antibiotic that may decrease hormone concentrations.

Moderate Interactions (Monitor Closely): - Antifungals (e.g., ketoconazole): can increase estrogen levels. - Selective serotonin reuptake inhibitors (SSRIs): may raise bleeding risk. - Hormone therapy (e.g., estrogen replacement): may augment overall estrogen exposure.